Hi Vinod,

Refering to the recent article regarding the denial of patients receiving Erbitux in the UK, you spoke of this concern.

In your opinion, are targeted thearpy drugs likely to take off in the near future and the longer term? Or will chemotherapy still remain gold standard thearpy for head and neck cancer patients.

In Europe, what % of patients roughly receive chemothearpy compared to targeted thearpy. How will this mix change for example by 2013?

What is the average cost of treatment for patients per year using chemothearpy in Europe compared to targeted thearpy?

Thanks,

Paljit